jcm-logo

Journal Browser

Journal Browser

Current Advances in Interventional Oncology

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Nuclear Medicine & Radiology".

Deadline for manuscript submissions: closed (25 September 2025) | Viewed by 1020

Special Issue Editor


E-Mail Website
Guest Editor
Clinic for Radiology and Nuclear Medicine, University Hospital Frankfurt, Goethe University, 60590 Frankfurt am Main, Germany
Interests: head and neck tumors; liver tumors; lung tumors; interventional oncology; interventional radiology; thermal ablation; transarterial chemoembolization
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

When resectability is not/no longer possible, or the patient does not respond to systemic chemotherapy, interventional oncology offers various minimally invasive treatment methods to achieve the highest possible survival rate and maintain or improve the patient‘s quality of life.

Interventional oncology/radiology plays an increasingly important role in either cancer diagnosis using imaging-guided biopsies or in the treatment of oncological disease using minimally invasive locoregional therapies, such as transarterial embolization (TAE), transarterial chemoembolization (TACE),  transarterial chemoperfusion (TACP), selective internal radiotherapy (SIRT), and transarterial radioembolization (TARE). Those therapies can be performed in an outpatient setting as they normally have low complication rates. They can be used as neoadjuvant, symptomatic, or palliative therapies for oncological diseases to improve survival and quality of life. TACE may also facilitate consecutive thermal ablation by reducing the size and/or number of metastases. Thermal ablation modalities are radiofrequency ablation (RFA), microwave ablation (MWA), laser-induced thermotherapy (LITT), cryoablation, and electroporisation. The thermal energy is used to destroy the tumor via thermal ablation. Thus, it can also be used curatively, and in many cases, it is an alternative to surgical treatment.

We look forward to submissions of original research articles and reviews related to this topic of interventional oncology in order to further advance research in this important field.

Prof. Dr. Thomas Vogl
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • interventional oncology/radiology
  • vascular locoregional therapies
  • thermal ablation
  • treatment options
  • imaging-guided biopsies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

9 pages, 202 KB  
Article
Interventional Treatments of Liver Metastases from Colorectal Cancer: Prognostic Factors and Subgroup Analyses
by Thomas J. Vogl, Lars Hammann, Hannah Stefan, Leon Vincent Stein and Hamzah Adwan
J. Clin. Med. 2025, 14(19), 7027; https://doi.org/10.3390/jcm14197027 - 4 Oct 2025
Viewed by 582
Abstract
Background/Objectives: This secondary analysis aims to evaluate various prognostic factors for overall survival (OS) and hepatic progression-free survival (hPFS) and to perform subgroup analyses regarding OS of patients with unresectable and chemotherapy-refractory liver metastases from colorectal cancer (LMCRC) treated by the combination [...] Read more.
Background/Objectives: This secondary analysis aims to evaluate various prognostic factors for overall survival (OS) and hepatic progression-free survival (hPFS) and to perform subgroup analyses regarding OS of patients with unresectable and chemotherapy-refractory liver metastases from colorectal cancer (LMCRC) treated by the combination therapy of transarterial chemoembolization (TACE) and microwave ablation (MWA) or with MWA alone. Methods: A total of 251 patients with unresectable and chemotherapy-refractory LMCRC were included retrospectively. Group A consisted of 184 patients who received a combination of TACE and MWA. A total of 67 patients were included in group B, who received only MWA. Group C summarizes the total number of 251 patients treated. For all groups, the influence of age, sex, number of metastases, the diameter and volume of the largest metastasis, and the occurrence of recurrence on OS and hPFS was determined using univariate cox regression analysis. OS was compared between patients with more than three metastases and those with three or fewer, as well as between patients with a diameter of largest metastasis of 3 cm or less with patients with a diameter of largest metastasis of more than 3 cm. The analysis of OS was carried out using the Kaplan–Meier method. Results: For all three groups, the parameters of age, sex, number of metastases, diameter and volume of the largest metastasis, complete ablation status, and recurrence were not significant prognostic factors for OS. The number of metastases had a statistically significant influence on hPFS in group C (p = 0.034) and trended towards significance in group A (p = 0.057). The mean OS of patients with three metastases or less was in all groups longer than patients with more than three metastases, however, with no statistically significant differences (p = 0.83, 0.451 and 0.84 for groups A, B and C, respectively). There were no significant differences regarding OS between patients with diameter of largest metastasis of 3 cm or less compared to patients with diameter of largest metastasis more than 3 cm in all groups (p = 0.316, 0.812 and 0.45 for groups A, B and C, respectively). Conclusions: We could not observe significant prognostic factors in the treatment of LMCRC on OS. Accordingly, patients with three metastases or less had non-significant longer OS than patients with more than three metastases. The number of metastases had a significant impact on hPFS of the whole patient cohort and borderline significant impact on hPFS in patients treated with TACE combined with MWA. Full article
(This article belongs to the Special Issue Current Advances in Interventional Oncology)
Back to TopTop